News

Apply for EU Prize for Women Innovators

Published on
| 2 years ago
Programmes
  • EIT

the HORIZON-EIT-2024-WomenInnovatorsPrize call  is now open for applications on the EU funding and tender portal. Deadline is 25 September 2024.

The European Prize for Women Innovators celebrates the women entrepreneurs behind Europe’s game-changing innovations, so that they may inspire other women and girls realise their full potential as the EU’s future scientists, innovators, and tech leaders.

This prize supports a culture within research and innovation organisations and companies allowing women to become the innovators and entrepreneurs of tomorrow.

The prize is awarded every year to women from across the EU and countries associated to Horizon Europe, who have transformed their ideas into disruptive innovations to benefit people and the planet.

Expected Impact:

The prize will boost public awareness of the potential, importance and contribution of women to the EU innovation ecosystem and create strong role models, inspiring more women to become innovators themselves.

 

 

 

Related news

myOverview

Sign up for personalised information

Stay informed about Horizon Europe, Digital Europe & EDF, filtered on what matters to you.

  • News in your domains
  • Event announcements
  • A personal dashboard
Sign up now

Only for stakeholders located in Flanders

Latest news

2050 articles available Browse all news
  • EIC

EIC Work Programme 2027 adopted

The 2027 work programme opens funding opportunities worth over €1.8 billion for strategic technologies and scaling up companies. The EIC work programme 2027 details the funding in six main schemes: EIC Pathfinder EIC Transition Advanced Innovation Challenges EIC Accelerator The EIC Strategic Technologies for Europe Platform (STEP) Scale Up EIC...

Read more

Testimonial

Methylomic – Hope & Improved outcomes for Crohn’s disease patients across Europe

The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.